Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michael T, Eaddy"'
Autor:
Charles R. Horres, Mohamed A. Adam, Zhifei Sun, Julie K. Thacker, Timothy J. Miller, Stuart A. Grant, Jeffrey Huang, Kirstie McPherson, Sanjiv Patel, Su Cheen Ng, Denise Veelo, Bart Geerts, Monty Mythen, Mark Foulger, Tim Collins, Michael Mythen, Mark Edwards, Denny Levett, Tristan Chapman, Imogen Fecher Jones, Julian Smith, John Knight, Michael Grocott, Thomas Sharp, Sandy Jack, Tom Armstrong, John Primrose, Adam B. King, Kye Higdon, Melissa Bellomy, Sandy An, Paul St. Jacques, Jon Wanderer, Matthew McEvoy, Anne C. Fabrizio, Michael C. Grant, Deborah Hobson, Jonathan Efron, Susan Gearhart, Bashar Safar, Sandy Fang, Christopher Wu, Elizabeth Wick, Leanne Darwin, John Moore, Aparna Rege, Jayanth Reddy, William Irish, Ahmad Zaaroura, Elizabeth Flores Vera, Deepak Vikraman, Todd Brennan, Debra Sudan, Kadiyala Ravindra, Deborah Watson, Manasee V. Shah, Brett A. Maiese, Michael T. Eaddy, Orsolya Lunacsek, An Pham, George J. Wan, Thomas Keen, Alexander B Stone, Christopher L. Wu, Elizabeth C. Wick, Rachel A. Anolik, Adam Glener, Thomas J. Hopkins, Scott T. Hollenbeck, Julie K. Marosky Thacker, Tracey Hong, Andrea Bisaillon, Peter Black, Alan So, Kelly Mayson, Rachel Forbes, Brad Koss, Tracy McGrane, Warren S. Sandberg, Jonathan Wanderer, Patrick Shanahan, John Rohan, Desirée Chappell, Carrie Chesher, Susan VanderBeek, Rebekah Kelly, Siamak Daneshmand, Soroush T. Bazargani, Hamed Ahmadi, Gus Miranda, Jie Cai, Anne K. Schuckman, Hooman Djaladat, Volz L., Milby J., Opeyemi Popoola, Tanisha Reid, Luciana Mullan, Mehrdad Rafizadeh, Richard Pitera
Publikováno v:
Perioperative Medicine. 5
A1 Effects of enhanced recovery pathways on renal function Charles R. Horres, Mohamed A. Adam, Zhifei Sun, Julie K. Thacker, Timothy J. Miller, Stuart A. Grant A2 Economic outcomes of enhanced recovery after surgery (ERAS) Jeffrey Huang A3 What does
Publikováno v:
American healthdrug benefits. 4(3)
Pharmacologic treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia often includes alpha-blockers and 5-alpha reductase inhibitors. Many clinicians use alpha-blockers for rapid symptom control, later adding 5-alpha re
Publikováno v:
PT : a peer-reviewed journal for formulary management. 36(8)
Recent clinical trials indicate that combining an alpha blocker for rapid symptom improvement and a 5-alpha reductase inhibitor (5-ARI) to reduce the risk of clinical progression of benign prostatic hyperplasia (BPH) may be an optimal approach to man
Publikováno v:
PT : a peer-reviewed journal for formulary management. 37(1)
We sought to assess the relationship between patient cost sharing; medication adherence; and clinical, utilization, and economic outcomes.We conducted a literature review of articles and abstracts published from January 1974 to May 2008. Articles wer
Autor:
Curtis A, Pettaway, Lois E, Lamerato, Michael T, Eaddy, Jessie K, Edwards, Susan L, Hogue, Martin M, Crane
Publikováno v:
BJU international. 108(8)
• To compare prostate cancer, prostate-related surgery and acute urinary retention rates, as well as associated healthcare resource use over 11 years in African American and Caucasian men with benign prostatic hyperplasia (BPH).• The BPH-related
Publikováno v:
The American journal of managed care. 14(5 Suppl 2)
To assess cost differences between dutasteride and finasteride use within the first year of initiating treatment for enlarged prostate (EP) among men agedor =65 years in a managed care setting.For this retrospective analysis, medical/pharmacy claims
Publikováno v:
The American journal of managed care. 14(5 Suppl 2)
To evaluate the likelihood of alpha-adrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients agedor =65 years with enlarged prostate.This retrospective analysis used 2003-2006 data representi
Autor:
Sundar Jagannath, Anuja Roy, Jonathan K Kish, Denise Globe, Orsolya Lunacsek, Michael T. Eaddy, Emil T Kuriakose, Joanne Willey, David Siegel
Publikováno v:
Blood. 126:3311-3311
Background: There are limited data on real-world treatment outcomes for novel agents used in the treatment of relapsed/refractory multiple myeloma (RRMM). These data are particularly important for patients who have already received bortezomib (BTZ) a
Publikováno v:
The American journal of managed care. 12
Publikováno v:
The American journal of managed care. 12
Costs of treating the 10 most prevalent diagnosed diseases in menor = 50 years of age were examined in hopes of identifying areas for better medical management and opportunities to decrease healthcare costs.A retrospective analysis of a large nationa